Narcotic Antagonists

"Narcotic Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Agents inhibiting the effect of narcotics on the central nervous system.

Descriptor ID	D009292
MeSH Number(s)	D27.505.696.543 D27.505.696.663.850.512 D27.505.954.427.550
Concept/Terms	Narcotic Antagonists Narcotic Antagonists Antagonists, Narcotic Opioid Receptor Antagonists Antagonists, Opioid Receptor Receptor Antagonists, Opioid Opioid Antagonists Antagonists, Opioid Competitive Opioid Antagonists Competitive Opioid Antagonists Antagonists, Competitive Opioid Opioid Antagonists, Competitive

Below are MeSH descriptors whose meaning is more general than "Narcotic Antagonists".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Narcotic Antagonists [D27.505.696.543]
Peripheral Nervous System Agents [D27.505.696.663]
Sensory System Agents [D27.505.696.663.850]
Narcotic Antagonists [D27.505.696.663.850.512]
Therapeutic Uses [D27.505.954]
Central Nervous System Agents [D27.505.954.427]
Narcotic Antagonists [D27.505.954.427.550]

Below are MeSH descriptors whose meaning is related to "Narcotic Antagonists".

Below are MeSH descriptors whose meaning is more specific than "Narcotic Antagonists".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Narcotic Antagonists" by people in this website by year, and whether "Narcotic Antagonists" was a major or minor topic of these publications.

Bar chart showing 100 publications over 22 distinct years, with a maximum of 12 publications in 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	0	1	1
2004	0	1	1
2007	0	2	2
2008	5	1	6
2009	1	1	2
2010	1	1	2
2011	2	1	3
2012	4	1	5
2013	3	3	6
2014	5	2	7
2015	3	1	4
2016	2	1	3
2017	11	1	12
2018	5	1	6
2019	3	0	3
2020	2	3	5
2021	0	4	4
2022	0	5	5
2023	0	3	3
2024	3	5	8
2025	5	4	9
2026	2	1	3

Below are the most recent publications written about "Narcotic Antagonists" by people in Profiles.

Hsu HE, Lodi S, Yan S, Bovell-Ammon BJ, Christine PJ, Tilhou AS, Bernson D, Novo P, Lee JD, Rotrosen J, Liebschutz JM, Walley AY, Larochelle MR. Buprenorphine-Naloxone vs Extended-Release Naltrexone Following Opioid Withdrawal Treatment. JAMA Netw Open. 2026 Jul 01; 9(7):e2623280.

View in: PubMed
Moore PQ, Mixson LS, Bolinski R, Colston DC, Cooper HLF, Crane HM, Devadas J, Feinberg J, Friedmann PD, Gicquelais RE, Jenkins WD, Khoury D, Korthuis PT, Smith G, Stopka TJ, Westergaard R, Young A, Pho MT. Correlates of Rural Naloxone Possession Among People Who Use Drugs: A Multi-State Cross-Sectional Analysis. J Rural Health. 2026 Jun; 42(3):e70187.

View in: PubMed
Votaw VR, Rosen RL, Peckham AD, London Z, Philpotts LL, Weiss RD, McHugh RK, Streck JM. Investigating the Effects of Buprenorphine Treatment on Depression Symptoms Among Adults with Opioid Use Disorder: A Scoping Review. J Dual Diagn. 2026 Apr; 22(2):158-190.

View in: PubMed
Chatterjee A, Chase RP, Chahine RA, Davis J, Dsouza N, Ellison S, Bagley SM, Fisher T, Glasgow L, Harris MTH, Huang TT, Holloway J, Lounsbury DW, Oga E, Asman K, Roberts SM, Sabounchi N, Surratt HL, Lines LM, Stadler HW, Taylor JL, Davis A. Local level of social inequity moderates implementation of evidence-based practices tailored to minoritized populations to reduce opioid overdose deaths. J Subst Use Addict Treat. 2026 Jan; 180:209828.

View in: PubMed
Rottapel RE, Stopka TJ, Friedmann PD, Hoskinson RA, Englander D, Calhoun N, Senst T, Gudas C, Koutoujian PJ, Farabee D. A protocol for a randomized comparison of extended-release versus sublingual buprenorphine among pre-trial detainees in jail. Addict Sci Clin Pract. 2025 10 27; 20(1):88.

View in: PubMed
Ostrowski SJ, Adkins A, Goldfarb D, Kukowski M, Stratton D, Barton DJ, Pizon AF. Transdermal buprenorphine patch-facilitated induction of sublingual buprenorphine in hospitalized patients receiving full agonist opioids: a retrospective cohort study. Clin Toxicol (Phila). 2025 Nov; 63(11):897-905.

View in: PubMed
Friedmann PD, Wilson D, Stopka TJ, Bernson D, Pivovarova E, Ferguson W, Hoskinson RA, Rottapel RE, Bovell-Ammon B, Gaba A, Morgan JR, Senst T, Hayes E, Evans EA. Medications for Opioid Use Disorder in County Jails - Outcomes after Release. N Engl J Med. 2025 Sep 11; 393(10):994-1003.

View in: PubMed
Ober AJ, Murray-Krezan C, Page K, Friedmann PD, Anderson J, Osilla KC, Ryzewicz S, Huerta S, Mazer MW, Hoskinson RA, Garvey R, Peltz A, Watkins KE, Nuckols T, IsHak WW, Mariano LT, Danovitch I. Hospital Addiction Consultation Service and Opioid Use Disorder Treatment: The START Randomized Clinical Trial. JAMA Intern Med. 2025 06 01; 185(6):624-633.

View in: PubMed
Broach JP, Rettger B, Gigliotti R, Chapman BP, Joseph J, Smiley A, Hunter M, Soucie N, Gross K, Babu KM, Weisberg SN. Creating Opioid Response Specialists: A Harm Reduction Initiative. Prehosp Emerg Care. 2025; 29(4):540-545.

View in: PubMed
Flanagan Balawajder E, Ducharme L, Taylor BG, Lamuda PA, Kolak M, Friedmann PD, Pollack HA, Schneider JA. Barriers to Universal Availability of Medications for Opioid Use Disorder in US Jails. JAMA Netw Open. 2025 04 01; 8(4):e255340.

View in: PubMed

People

Explore

Similar Concepts

Top Journals